Valuation: Clarity Pharmaceuticals Ltd

Market Cap 925M 663M 568M 532M 487M 913M 63.46B 6.28B 2.45B 31.88B 2.49B 2.44B 105B P/E 2026 *
-8.43x
P/E 2027 * -7.75x
Enterprise Value 764M 548M 469M 439M 402M 754M 52.41B 5.19B 2.02B 26.33B 2.06B 2.01B 87.09B EV / Sales 2026 *
-
EV / Sales 2027 * 938x
Free-Float
79.07%
Yield 2026 *
-
Yield 2027 * -
1 day-5.34%
1 week-5.70%
Current month+4.64%
1 month+5.98%
3 months-9.49%
6 months-29.34%
Current year-26.63%
1 week 2.44
Extreme 2.44
2.74
1 month 2.03
Extreme 2.03
2.96
Current year 1.8
Extreme 1.8
4.26
1 year 1.8
Extreme 1.8
5.87
3 years 0.98
Extreme 0.975
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
Manager TitleAgeSince
Chief Executive Officer - 11/10/2024
Chief Executive Officer - 01/01/2010
Director of Finance/CFO - 04/04/2022
Director TitleAgeSince
Chairman - 01/11/2013
Director/Board Member - 01/10/2010
Director/Board Member 72 29/03/2016
Date Insider Type Main position Quantity % Market Cap.
11/28/25 A Free

Chief Operating Officer

199,909 0.0537%
11/28/25 A Free

Chief Operating Officer

287,530 0.0773%
11/28/25 A Free

Chairman

744,922 0.2003%
Change 5-day change 1-year change 3-year change Capi.($)
-5.34%-5.70%-26.84%+141.95% 663M
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.82% 65.85B
+5.12%+25.22%+5.13%-5.86% 29.28B
+0.55%+1.64%-4.63%+480.92% 27.47B
+2.74%+12.98%+54.92%+25.77% 26.7B
+0.47%+6.12%+37.01%-15.31% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+151.77% 13.4B
Average +0.59%+6.96%+50.50%+192.11% 29.02B
Weighted average by Cap. +0.73%+9.45%+57.83%+157.82%

Financials

2026 *2027 *
Net sales - 933K 669K 573K 536K 491K 921K 64.01M 6.34M 2.47M 32.16M 2.51M 2.46M 106M
Net income -108M -77.38M -66.28M -62.02M -56.77M -107M -7.4B -733M -286M -3.72B -291M -284M -12.3B -121M -86.68M -74.25M -69.47M -63.59M -119M -8.29B -821M -320M -4.17B -325M -318M -13.78B
Net Debt -161M -115M -98.85M -92.5M -84.67M -159M -11.04B -1.09B -426M -5.55B -433M -424M -18.35B -49.5M -35.48M -30.39M -28.44M -26.03M -48.85M -3.39B -336M -131M -1.71B -133M -130M -5.64B
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Employees
-
Date Price Change Volume
21/08/26 A$2.480 -5.34% 2,460,943
20/08/26 A$2.620 +5.22% 2,433,038
19/08/26 A$2.490 -3.11% 2,161,243
18/08/26 A$2.570 -0.77% 1,542,583
17/08/26 A$2.590 -1.52% 1,215,544
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.480AUD
Average target price
7.202AUD
Spread / Average Target
+190.42%

Annual profits - Rate of surprise